公开(公告)号：US08822493B2

公开(公告)日：2014-09-02

申请号：US13794583

申请日：2013-03-11

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Michelle Arkin ,  Jennifer Hyde ,  Duncan Walker ,  Jasmin Wright

IPC: A61K31/7068 ,  A61K31/4375 ,  A61K31/555 ,  A61K31/4745 ,  A61K9/00 ,  A61K31/44 ,  A61K41/00 ,  C07D471/04 ,  A61K47/12 ,  A61K45/06 ,  A61K38/18

CPC classification number: A61K31/4375 ,  A61K9/0019 ,  A61K31/282 ,  A61K31/337 ,  A61K31/395 ,  A61K31/407 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/555 ,  A61K31/585 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/15 ,  A61K38/1816 ,  A61K41/00 ,  A61K45/06 ,  A61K47/12 ,  C07D471/04 ,  F24S10/70 ,  F24S50/40 ,  F24S60/30 ,  F24S80/60 ,  H01L31/0547 ,  H02S40/38 ,  Y02E10/40 ,  Y02E10/52 ,  A61K2300/00

Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.

Abstract translation: 本发明涉及SNS-595及使用其的癌症治疗方法。

公开(公告)号：US20180291001A1

公开(公告)日：2018-10-11

申请号：US15875629

申请日：2018-01-19

Applicant: BIOGEN MA INC. ,  Sunesis Pharmaceuticals, Inc.

Inventor： Brian T. Hopkins ,  Xiongwei Cai ,  Timothy R. Chan ,  Patrick Conlon ,  Michael Humora ,  Tracy J. Jenkins ,  J. Michael Macphee ,  Xianglin Shi ,  Ross A. Miller ,  Andrew Thompson

IPC: C07D401/14 ,  C07D207/16 ,  C07D211/56 ,  C07D207/28 ,  C07D401/04

CPC classification number: C07D401/14 ,  C07B2200/13 ,  C07D207/16 ,  C07D207/28 ,  C07D211/56 ,  C07D401/04

Abstract: The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.

公开(公告)号：US09873693B2

公开(公告)日：2018-01-23

申请号：US14328256

申请日：2014-07-10

Applicant: Sunesis Pharmaceuticals, Inc. ,  Millennium Pharmaceuticals, Inc.

Inventor： Kenneth Egnard Lind ,  Kathy Cao ,  Edward Yin-shiang Lin ,  Thinh Ba Nguyen ,  Bradley T. Tangonan ,  Daniel A. Erlanson ,  Kevin Guckian ,  Robert Lowell Simmons ,  Wen-cherng Lee ,  Lihong Sun ,  Stig Hansen ,  Nuzhat Pathan ,  Lei Zhang

IPC: A61K31/5377 ,  A61K31/506 ,  A61K31/519 ,  A61K31/4985 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/4436 ,  A61K31/443 ,  A61K31/4412 ,  C07D487/04 ,  C07D471/04 ,  C07D417/14 ,  C07D417/12 ,  C07D413/14 ,  C07D413/12 ,  C07D409/14 ,  C07D409/12 ,  C07D405/14 ,  C07D405/12 ,  C07D401/14 ,  C07D401/12 ,  C07D211/86 ,  C07D213/64 ,  C07D407/14

CPC classification number: C07D471/04 ,  A61K31/4412 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  C07D211/86 ,  C07D213/64 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04

Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.

公开(公告)号：US09757363B2

公开(公告)日：2017-09-12

申请号：US14996025

申请日：2016-01-14

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Daniel C. Adelman ,  Jeffrey A. Silverman

IPC: A61K31/4375 ,  A61K9/00 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/555 ,  A61K38/18 ,  A61K41/00 ,  A61K45/06 ,  A61K31/7068 ,  C07D471/04 ,  A61K47/12

CPC classification number: A61K31/4375 ,  A61K9/0019 ,  A61K31/282 ,  A61K31/337 ,  A61K31/395 ,  A61K31/407 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/52 ,  A61K31/555 ,  A61K31/585 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/15 ,  A61K38/1816 ,  A61K41/00 ,  A61K45/06 ,  A61K47/12 ,  C07D471/04 ,  F24S10/70 ,  F24S50/40 ,  F24S60/30 ,  F24S80/60 ,  H01L31/0547 ,  H02S40/38 ,  Y02E10/40 ,  Y02E10/52 ,  A61K2300/00

Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.

公开(公告)号：US20170158686A1

公开(公告)日：2017-06-08

申请号：US15380515

申请日：2016-12-15

Applicant: Millennium Pharmaceuticals, Inc. ,  Sunesis Pharmaceuticals, Inc.

Inventor： Weirong CHEN ,  Jennifer Cossrow ,  Lloyd Franklin ,  Bing Guan ,  John Howard Jones ,  Gnanasambandam Kumaravel ,  Benjamin Lane ,  Adam Littke ,  Alexey Lugovskoy ,  Hairuo Peng ,  Noel Powell ,  Brian C. Raimundo ,  Hiroko Tanaka ,  Jeffrey Vessels ,  Thomas Wynn ,  Zhili Xin

IPC: C07D417/14 ,  A61K31/506 ,  C07D417/12 ,  A61K31/5377 ,  C07D413/14 ,  C07D403/12 ,  A61K31/52 ,  C07D471/04 ,  C07F9/6558 ,  A61K31/675 ,  C07D401/12 ,  C07D401/14 ,  A61K45/06 ,  C07D473/00

CPC classification number: C07D417/14 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D473/00 ,  C07D487/04 ,  C07F9/65583

Abstract: The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

公开(公告)号：US20170119745A1

公开(公告)日：2017-05-04

申请号：US15173506

申请日：2016-06-03

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Daniel C. Adelman ,  Jeffrey A. Silverman ,  Glenn Michelson ,  Caroline Dame Scatena

IPC: A61K31/4375 ,  A61K31/7068

CPC classification number: A61K31/4375 ,  A61K31/513 ,  A61K31/7068 ,  C07D417/14 ,  A61K2300/00

Abstract: Methods of treating, preventing or managing hematologic disorders, such as leukemia are disclosed. The methods encompass the administration of SNS-595. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with Ara-C. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

公开(公告)号：US20170101404A1

公开(公告)日：2017-04-13

申请号：US15156230

申请日：2016-05-16

Applicant: Sunesis Pharmaceuticals, Inc.

Inventor： Daniel C. Adelman ,  Marc J. Evanchik ,  Anantha Sudhakar ,  Jeffrey William Jacobs ,  Jeffrey A. Silverman

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/4375 ,  A61K31/4745 ,  C07D417/14 ,  A61K2300/00

Abstract: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.

公开(公告)号：US20160331756A1

公开(公告)日：2016-11-17

申请号：US14966821

申请日：2015-12-11

Applicant: Sunesis Pharmaceuticals, Inc. ,  Millennium Pharmaceuticals, Inc.

Inventor： Joseph Arndt ,  Timothy Chan ,  Kevin Guckian ,  Gnanasambandam Kumaravel ,  Wen-Cherng Lee ,  Edward Yin-Shiang Lin ,  Daniel Scott ,  Lihong Sun ,  Jermaine Thomas ,  Kurt van Vloten ,  Deping Wang ,  Lei Zhang ,  Daniel Erlanson

IPC: A61K31/5383 ,  A61K31/452 ,  A61K31/437 ,  A61K31/4985 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/519 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/498 ,  A61K31/497 ,  A61K31/53 ,  A61K31/444 ,  A61K31/517

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/452 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/5383 ,  C07D213/82 ,  C07D213/85 ,  C07D241/26 ,  C07D241/28 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D417/14 ,  C07D473/34 ,  C07D487/04 ,  C07D491/052 ,  C07D498/04 ,  C07D519/00

Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Abstract translation: 本发明提供了可用作PDK1抑制剂的化合物。 本发明还提供了其组合物，以及治疗PDK1介导的疾病的方法。

公开(公告)号：US20150202189A1

公开(公告)日：2015-07-23

申请号：US14476606

申请日：2014-09-03

Applicant: SUNESIS PHARMACEUTICALS, INC.

Inventor： Rachael E. HAWTIN ,  Judith A. Fox

IPC: A61K31/4375 ,  A61K45/06

CPC classification number: A61K31/4375 ,  A61K31/045 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  A61K2300/00

Abstract: Methods of using SNS-595 for treatment of a subject having cancer with BRCA2 mutation are described. In certain embodiments, the methods comprise administering a therapeutically effective amount of SNS-595 to a subject in need thereof.

Abstract translation: 描述了使用SNS-595治疗患有BRCA2突变的患者的方法。 在某些实施方案中，所述方法包括向有需要的受试者施用治疗有效量的SNS-595。

公开(公告)号：US20140205680A1

公开(公告)日：2014-07-24

申请号：US14056877

申请日：2013-10-17

Applicant: SUNESIS PHARMACEUTICALS, INC.

Inventor： Daniel C. Adelman ,  Jeffrey A. Silverman ,  Michelle Arkin ,  Jennifer Hyde ,  Duncan Walker ,  Jasmin Wright

IPC: A61K31/4375 ,  A61K45/06

CPC classification number: A61K31/4375 ,  A61K31/513 ,  A61K45/06

Abstract: Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods are also disclosed.

Abstract translation: 公开了治疗，预防或治疗癌症的方法，包括某些白血病。 该方法包括给予对映体纯的（+） - 1,4-二氢-7 - [（3S，4S）-3-甲氧基-4-（甲基氨基）-1-吡咯烷基] -4-氧代-1-（2 -1,3-噻唑基）-1,8-二氮杂萘-3-羧酸。 还提供了使用化合物与化疗，放射治疗，激素治疗，生物治疗或免疫治疗的治疗方法。 还公开了适用于该方法的药物组合物和单一单位剂型。